Overview

Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to demonstrate pharmacodynamic comparability between the pantoprazole spheroid formulation and the marketed tablet formulation.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Pantoprazole
Criteria
Inclusion Criteria:

- GERD and a history of Erosive Esophagitis documented by endoscopy

- H. pylori negative

Exclusion Criteria:

- Gastrointestinal conditions such as esophageal stricture, esophageal varices, previous
vagotomy

- Achlorhydria